Table 5

Subfoveal versus juxtafoveal myopic CNV: visual and anatomical outcome after intravitreal bevacizumab injection

Outcome	Baseline		1 year		2 years		3 years
Outcome	Subfoveal (18 eyes)	Juxtafoveal (14 eyes)	Subfoveal (18 eyes)	Juxtafoveal (14 eyes)	Subfoveal (18 eyes)	Juxtafoveal (14 eyes)	Subfoveal (17 eyes)	Juxtafoveal (10 eyes)
BCVA (No of ETDRS letters)	21.4±10.3	41.3±14.2	42.2±11.9	52.1±6.9	41.7±13.1	52.9±8.2	40.4±13.5	54.0±5.8
p Value		<0.0001^*		0.006^*		0.006^*		0.001^*
BCVA change (No of ETDRS letters)			20.8±7.2	10.9±10.9	20.3±8.1	11.6±14.4	18.7±10.7	12.8±14.8
p Value				0.004^*		0.04^*		0.2^*
CNV area (mm²)	0.88±0.84	0.28±0.16	0.44±0.58	0.16±0.13	0.45±0.59	0.16±0.13	0.54±0.68	0.18±0.15
p Value		0.008^*		0.07^*		0.05^*		0.05^*
CNV closure rate (%)			13/18 (72%)	12/14 (86%)	18/18 (100%)	12/14 (86%)	17/17 (100%)	10/10 (100%)
p Value				0.4^†		0.2^†		–
No of injections			4.4±1.8	3.7±1.5	1.3±2.0	0.7±1.8	0.5±1.0	0.5±1.1
p Value				0.3^*		0.4^*		0.9^*

Values are mean±SD unless otherwise indicated.
↵* Unpaired t test with Levene's test for equality of variances.
↵† Fisher's exact test.
BCVA, best corrected visual acuity; CNV, choroidal neovascularisation; ETDRS, Early Treatment Diabetic Retinopathy Study.